Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Drivers of Clinical Trial Participation—Demographics, Disparities, and Eligibility Criteria

Drivers of Clinical Trial Participation—Demographics, Disparities, and Eligibility Criteria Opinion EDITORIAL Drivers of Clinical Trial Participation— Demographics, Disparities, and Eligibility Criteria Grace Mishkin, MPH; Fernanda Arnaldez, MD; S. Percy Ivy, MD In the current issue of JAMA Oncology, Unger et al provide an mographics and socioeconomic status, comorbidities inde- pendently predicted the diminished likelihood that trial dis- overview from SWOG in response to the recommendations to modernize eligibility criteria for clinical trials developed by the cussions, trial offers, or trial participation would occur. From American Society of Oncology (ASCO), Friends of Cancer Re- the aggregated analysis, the authors concluded that decreas- search (Friends), and the Na- ing barriers to trial participation through the liberalization of tional Cancer Institute (NCI) eligibility would have a positive influence on trial offers and Related article page 326 to support less restrictive eli- trial participation. 2-6 gibility criteria to broaden participation in clinical trials. To provide some context on the limitations of this study, At this point, there is little doubt among oncology practi- it is important to clearly distinguish the differences between tioners that addressing unnecessarily restrictive inclusion comorbidities and eligibility criteria. Many eligibility criteria criteria in clinical trials not only would facilitate enrollment are not comorbidities (eg, disease-related requirements and cer- http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Oncology American Medical Association

Drivers of Clinical Trial Participation—Demographics, Disparities, and Eligibility Criteria

JAMA Oncology , Volume 5 (3) – Mar 10, 2019

Loading next page...
 
/lp/american-medical-association/drivers-of-clinical-trial-participation-demographics-disparities-and-0t9fxKzLV8
Publisher
American Medical Association
Copyright
Copyright 2019 American Medical Association. All Rights Reserved.
ISSN
2374-2437
eISSN
2374-2445
DOI
10.1001/jamaoncol.2018.5949
Publisher site
See Article on Publisher Site

Abstract

Opinion EDITORIAL Drivers of Clinical Trial Participation— Demographics, Disparities, and Eligibility Criteria Grace Mishkin, MPH; Fernanda Arnaldez, MD; S. Percy Ivy, MD In the current issue of JAMA Oncology, Unger et al provide an mographics and socioeconomic status, comorbidities inde- pendently predicted the diminished likelihood that trial dis- overview from SWOG in response to the recommendations to modernize eligibility criteria for clinical trials developed by the cussions, trial offers, or trial participation would occur. From American Society of Oncology (ASCO), Friends of Cancer Re- the aggregated analysis, the authors concluded that decreas- search (Friends), and the Na- ing barriers to trial participation through the liberalization of tional Cancer Institute (NCI) eligibility would have a positive influence on trial offers and Related article page 326 to support less restrictive eli- trial participation. 2-6 gibility criteria to broaden participation in clinical trials. To provide some context on the limitations of this study, At this point, there is little doubt among oncology practi- it is important to clearly distinguish the differences between tioners that addressing unnecessarily restrictive inclusion comorbidities and eligibility criteria. Many eligibility criteria criteria in clinical trials not only would facilitate enrollment are not comorbidities (eg, disease-related requirements and cer-

Journal

JAMA OncologyAmerican Medical Association

Published: Mar 10, 2019

References